Compare LSCC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSCC | INCY |
|---|---|---|
| Founded | 1983 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2B | 17.0B |
| IPO Year | 1994 | 1994 |
| Metric | LSCC | INCY |
|---|---|---|
| Price | $119.10 | $122.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | ★ $103.75 | $103.52 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | 0.29 | ★ 1.47 |
| Revenue | $385,961,000.00 | ★ $3,394,635,000.00 |
| Revenue This Year | $36.12 | $10.44 |
| Revenue Next Year | $19.98 | $10.99 |
| P/E Ratio | $398.10 | ★ $85.72 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $60.50 | $81.09 |
| 52 Week High | $157.01 | $132.60 |
| Indicator | LSCC | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 48.53 |
| Support Level | $110.97 | $121.61 |
| Resistance Level | $124.30 | $131.70 |
| Average True Range (ATR) | 3.88 | 3.20 |
| MACD | 0.28 | -0.64 |
| Stochastic Oscillator | 41.16 | 19.86 |
Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.